[go: up one dir, main page]

ES2063350T3 - Nuevas proteinas con efecto inhibidor del tnf y su produccion. - Google Patents

Nuevas proteinas con efecto inhibidor del tnf y su produccion.

Info

Publication number
ES2063350T3
ES2063350T3 ES90906924T ES90906924T ES2063350T3 ES 2063350 T3 ES2063350 T3 ES 2063350T3 ES 90906924 T ES90906924 T ES 90906924T ES 90906924 T ES90906924 T ES 90906924T ES 2063350 T3 ES2063350 T3 ES 2063350T3
Authority
ES
Spain
Prior art keywords
ala phe
pct
val ala
gln val
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90906924T
Other languages
English (en)
Other versions
ES2063350T5 (es
Inventor
Hans-Georg Lemaire
Heinz Hillen
Achim Moeller
Lothar Daum
Thomas Doerper
Thomas Subkowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25880678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2063350(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BASF SE filed Critical BASF SE
Publication of ES2063350T3 publication Critical patent/ES2063350T3/es
Application granted granted Critical
Publication of ES2063350T5 publication Critical patent/ES2063350T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)

Abstract

Proteínas, que en su forma glicosilada original tienen un peso molecular de aproximadamente42.000 dalton y en el término N presentan la secuencia de aminoácidosXaa Thr Pro Tyr Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu Arg Gluen la cual Xaa representa un átomo de hidrógeno, un resto de fenilalanina (Phe) o las secuencias deaminoácidos Ala Phe, Val Ala Phe, Gln Val Ala Phe, Ala Gln Val Ala Phe, Pro Ala Gln Val Ala Phe o Leu Pro Ala Gln Val Ala Phe, y sus muteínas, que se forman por intercambio, deleción o adiciónapropiadas de aminoácidos o péptidos o por variación del resto glicosídico, sin que con ello disminuyaacusadamente el efecto de las proteínas.
ES90906924T 1989-05-09 1990-05-04 Nuevas proteinas con efecto inhibidor del tnf y su obtencion. Expired - Lifetime ES2063350T5 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE3915072 1989-05-09
DE3915072 1989-05-09
DE3922089A DE3922089A1 (de) 1989-05-09 1989-07-05 Neue proteine und ihre herstellung
DE3922089 1989-07-05

Publications (2)

Publication Number Publication Date
ES2063350T3 true ES2063350T3 (es) 1995-01-01
ES2063350T5 ES2063350T5 (es) 2007-09-16

Family

ID=25880678

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90906924T Expired - Lifetime ES2063350T5 (es) 1989-05-09 1990-05-04 Nuevas proteinas con efecto inhibidor del tnf y su obtencion.

Country Status (11)

Country Link
US (1) US5344915A (es)
EP (1) EP0471701B2 (es)
JP (6) JP3290651B2 (es)
AT (1) ATE113063T1 (es)
AU (1) AU633913B2 (es)
CA (2) CA2425101A1 (es)
DE (3) DE3922089A1 (es)
ES (1) ES2063350T5 (es)
HU (1) HU208162B (es)
NL (1) NL300013I2 (es)
WO (1) WO1990013575A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US6479632B1 (en) 1988-09-12 2002-11-12 Yeda Research And Development Co. Ltd. Tumor necrosis factor inhibitory protein and its purification
ES2238070T3 (es) 1989-04-21 2005-08-16 Amgen Inc. Receptor del tnf, proteina ligante del tnf y adn codante para estos.
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6262239B1 (en) 1989-05-18 2001-07-17 Yeda Research And Development Co., Ltd. TNF receptor-specific antibodies
US6232446B1 (en) 1989-05-18 2001-05-15 Yeda Research And Development Co. Ltd. TNF ligands
CA2017025C (en) * 1989-05-18 2008-07-22 David Wallach Tumor necrosis factor binding protein ii, its purification and antibodies thereto
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) * 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
ATE236249T1 (de) * 1989-09-12 2003-04-15 Hoffmann La Roche Tfn-bindende proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
WO1992001002A1 (fr) * 1990-07-11 1992-01-23 Teijin Limited Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation
JP2864434B2 (ja) * 1991-01-18 1999-03-03 サイナーゲン，インコーポレーテッド 腫瘍壊死因子媒介疾患の治療方法
WO1993004375A1 (en) * 1991-08-23 1993-03-04 Nchip, Inc. Burn-in technologies for unpackaged integrated circuits
DE69230862T2 (de) * 1991-10-15 2000-12-14 Michael F. Mullarkey Rezeptoren zur Behandlung von Entzündungen vom verzögerten Typ
NZ251820A (en) * 1992-03-30 1996-07-26 Immunex Corp Fusion proteins with tnf-r (tumour necrosis factor-receptor) peptide linked to another tnf-r or an il-1r (interleukin-1-receptor) peptide
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
CA2273852C (en) 1996-12-06 2009-09-29 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
JP2001513754A (ja) 1996-12-06 2001-09-04 アムジェン インコーポレイテッド Ｔｎｆ媒介疾患を処置するためのｔｎｆ結合タンパク質を使用する組み合わせ治療
JP2002516069A (ja) 1997-09-30 2002-06-04 ファルマシア・アンド・アップジョン・カンパニー Ｔｎｆ関連死リガンド
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2001064889A2 (en) 2000-03-02 2001-09-07 Xencor Tnf-alpha variants for the treatment of tnf-alpha related disorders
WO2003002187A2 (en) * 2001-06-26 2003-01-09 Photomed Technologies, Inc. Multiple wavelength illuminator
SG10201603108QA (en) 2001-06-26 2016-05-30 Amgen Inc Antibodies To OPGL
WO2004060911A2 (en) * 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
JP2013507124A (ja) * 2009-10-09 2013-03-04 アナフォア インコーポレイテッド Ｉｌ−２３ｒを結合するポリペプチド
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
ES2753216T3 (es) 2010-01-15 2020-04-07 Amgen K A Inc Formulación de anticuerpos anti-IL17RA y regímenes terapéuticos para el tratamiento de la psoriasis
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
KR102530900B1 (ko) 2014-03-31 2023-05-12 암젠 케이-에이, 인크. 손발톱 및 두피 건선의 치료 방법
CN108727474B (zh) * 2018-06-11 2020-07-28 北京市农林科学院 具有消脂护肝功能的毛木耳提取物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4677063A (en) * 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
DK172052B1 (da) * 1984-12-21 1997-09-29 Otsuka Pharma Co Ltd Antitumor-aktivt stof, fremgangsmåde til dets fremstilling, lægemiddel indeholdende stoffet, gen kodende for stoffet, vektor indeholdende genet samt rekombinant mikroorganisme transformet med en sådan vektor
EP0251037B1 (en) * 1986-06-20 1994-06-15 Dainippon Pharmaceutical Co., Ltd. Novel human TNF polypeptide mutants and DNAs encoding said mutants
JPH07106158B2 (ja) * 1986-12-04 1995-11-15 サントリー株式会社 抗腫瘍活性を有する新規ポリペプチドおよびその製造法
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it

Also Published As

Publication number Publication date
JPH04505014A (ja) 1992-09-03
EP0471701B2 (de) 2007-03-07
EP0471701B1 (de) 1994-10-19
JP2009167220A (ja) 2009-07-30
CA2050300A1 (en) 1990-11-10
CA2425101A1 (en) 1990-11-15
HU208162B (en) 1993-08-30
JP2002302500A (ja) 2002-10-18
JP2004043502A (ja) 2004-02-12
NL300013I2 (nl) 2001-04-02
US5344915A (en) 1994-09-06
HU903740D0 (en) 1992-01-28
JP3290651B2 (ja) 2002-06-10
JP2005272473A (ja) 2005-10-06
HUT58352A (en) 1992-02-28
CA2050300C (en) 2003-04-08
ATE113063T1 (de) 1994-11-15
DE3922089A1 (de) 1990-12-13
EP0471701A1 (de) 1992-02-26
AU633913B2 (en) 1993-02-11
JP4001604B2 (ja) 2007-10-31
DE10075019I2 (de) 2005-06-23
DE59007517D1 (de) 1994-11-24
ES2063350T5 (es) 2007-09-16
JP2007084554A (ja) 2007-04-05
NL300013I1 (nl) 2000-10-02
WO1990013575A1 (de) 1990-11-15
DE10075019I1 (de) 2000-09-21
AU5532490A (en) 1990-11-29

Similar Documents

Publication Publication Date Title
ES2063350T3 (es) Nuevas proteinas con efecto inhibidor del tnf y su produccion.
Ling et al. Isolation, primary structure, and synthesis of human hypothalamic somatocrinin: growth hormone-releasing factor.
KR900017607A (ko) 프로테이나아제 억제제, 이것의 제조방법 및 이들을 함유한 의약품
KR940703854A (ko) 사람 쿠니즈형 프로테아제 저해제 변이체(a human kunitz-type protease inhibitor variant)
IL104314A0 (en) Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
DE3486154D1 (de) Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung.
AU5963290A (en) Inhibition of the n-end rule pathway in living cells
DE3875538D1 (de) Aminoluciferine, verfahren zu deren herstellung und ihre verwendung.
EP0661985A4 (en) PEPTIDE OR CD8 BINDING DOMAIN.
Gagnon et al. Primary structure of the A chain of human complement-classical-pathway enzyme C1r. N-terminal sequences and alignment of autolytic fragments and CNBr-cleavage peptides
ATE124955T1 (de) Substrat-peptide.
Wakabayashi et al. Amino Acid Sequences of Two Ferredoxins from Phytolacca esculenta Gene Duplication and Speciation
ATE140234T1 (de) Neue inhibitorische peptide
ATE50267T1 (de) Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren.
AU2676399A (en) Novel cystine knot protein and materials and methods for making it
ATE25984T1 (de) Pharmakologisch aktive peptide.
NO20016341L (no) Inhibitorer for integrinet <alfa>v<beta>6
Tonoike et al. Amino acid sequence of an amyloidogenic Bence Jones protein in myeloma‐associated systemic amyloidosis
JPH08269090A (ja) 新規ぺプチド
KOTAKI et al. Studies on Insulin: IV. On the Amino Acid Composition of the Glvcyl Chain of Bonito Insulin-I
RU94036002A (ru) Ингибитор протеазы, днк, вектор, клетка, способ получения ингибитора, фармацевтическая композиция
GEP19981435B (en) Peptides with Organo-Protective Activity, Pharmaceutical Composition and the Use Thereof
KR940703855A (ko) 사람 쿠니즈형 프로테아제 저해제 변이체(a human kunitz-type protease inhibitor variant)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 471701

Country of ref document: ES

SPCG Supplementary protection certificate granted

Free format text: ETANERCEP (ENBREL)

Spc suppl protection certif: C200000015

Filing date: 20000731

Expiry date: 20150203

Effective date: 20031205